News brief­ing: Bausch Health clos­ing in on deal to ac­quire Al­le­gro as­sets; PharmAbcine strikes deal with Sam­sung Bi­o­log­ics to de­vel­op an­ti­body pro­gram

Bausch Health is clos­ing in on a deal that would al­low it to buy out all of Al­le­gro Oph­thalmics’ eye-re­lat­ed as­sets — in­clud­ing the rights to lead can­di­date risute­ganib — for $50 mil­lion.

The pay­ment would be made in two tranch­es: $10 mil­lion at sign­ing, and $40 mil­lion in 2021.

Risute­ganib is in clin­i­cal de­vel­op­ment for in­ter­me­di­ate dry Age-re­lat­ed Mac­u­lar De­gen­er­a­tion (AMD). It’s ex­pect­ed to en­ter two con­cur­rent Phase III tri­als for that in­di­ca­tion in the next year. The drug is al­so be­ing test­ed in pa­tients with di­a­bet­ic mac­u­lar ede­ma (DME), and last year met the pri­ma­ry end­point in a Phase II study, with 48% of pa­tients gain­ing 8 or more let­ters in vi­su­al acu­ity from base­line at week 28, com­pared to 7% in the con­trol group at week 12.

The deal aligns with Bausch’s plan to build up its eye health busi­ness, Bausch + Lomb. “The ad­di­tion of the oph­thalmic as­sets of Al­le­gro would sig­nif­i­cant­ly en­hance our com­pre­hen­sive port­fo­lio of prod­ucts for AMD,” Bausch Health CEO and chair­man Joseph Pa­pa said in a state­ment. “If ap­proved, risute­ganib may be the first treat­ment in­di­cat­ed to help re­verse vi­sion loss due to dry AMD and would ad­dress a sig­nif­i­cant un­met med­ical need af­fect­ing mil­lions of peo­ple glob­al­ly.” — Nicole De­Feud­is

PharmAbcine strikes deal with Sam­sung Bi­o­log­ics to de­vel­op an­ti­body pro­gram

PharmAbcine has inked a deal with Sam­sung Bi­o­log­ics to help get its PMC-403 pipeline off the ground. Sam­sung will pro­vide the “full scope of its CDO ser­vices,” in­clud­ing cell line de­vel­op­ment, process de­vel­op­ment, cGMP clin­i­cal man­u­fac­tur­ing and IND fil­ing sup­port, ac­cord­ing to the com­pa­nies.

PMC-403, an ag­o­nis­tic an­ti­body, binds to the hu­man Tie2 re­cep­tor. It’s in de­vel­op­ment for both non-oc­u­lar and oc­u­lar patho­log­i­cal ves­sel-re­lat­ed dis­eases. If all goes well, PharmAbcine ex­pects to en­ter it in a glob­al clin­i­cal tri­al in oph­thal­mol­o­gy in 2022. The com­pa­ny is al­so col­lab­o­rat­ing with the NI­AID, which is as­sess­ing the drug as a po­ten­tial sys­temic cap­il­lary leak syn­drome treat­ment.

“This marks a sig­nif­i­cant turn­ing point for PharmAbcine be­cause we are fi­nal­ly tak­ing the ac­tu­al steps to ex­pand the in­di­ca­tions of our an­gio­gen­e­sis as­sets be­yond on­col­o­gy,” PharmAbcine CEO Jin-San Yoo said in a state­ment. “We ex­pect to use PMC-403 mol­e­cules pro­duced un­der this con­tract in not on­ly pre­clin­i­cal re­search col­lab­o­ra­tion with NI­AID for SCLS ther­a­peu­tics but al­so our own R&D ef­forts to treat var­i­ous vas­cu­lar dis­eases.” — Nicole De­Feud­is 

In his­toric Covid-19 ad­comm, vac­cine ex­perts de­bate a sea of ques­tions — but of­fer no clear an­swers

The most widely anticipated and perhaps most widely watched meeting in the FDA’s 113-year history ended late Thursday night with a score of questions and very few answers.

For nearly 9 hours, 18 different outside experts listened to public health agencies and foundations present how the United States’ Covid-19 vaccine program developed through October, and they debated where it should go from there: Were companies testing the right metrics in their massive trials? How long should they track patients before declaring a vaccine safe or effective? Should a vaccine, once authorized, be given to the volunteers in the placebo arm of a trial?

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,400+ biopharma pros reading Endpoints daily — and it's free.

Pascal Soriot, AstraZeneca CEO (Zach Gibson/Bloomberg via Getty Images)

UP­DAT­ED: FDA gives As­traZeneca the thumbs-up to restart PhI­II Covid-19 vac­cine tri­als, and J&J is prepar­ing to re­sume its study

Several countries had restarted their portions of AstraZeneca’s global Phase III Covid-19 vaccine trial after the study was paused worldwide in early September, but the US notably stayed on the sidelines — until now. Friday afternoon the pharma giant announced the all clear from US regulators. And on top of that, J&J announced Friday evening that it’s preparing to resume its own Phase III vaccine trial.

Ul­tragenyx in­jects $40M to grab Solid's mi­crody­s­trophin trans­gene — while side­step­ping the AAV9 vec­tor that stirred up safe­ty fears

Since before Ilan Ganot started Solid Bio to develop a gene therapy for kids like his son, who has Duchenne muscular dystrophy, Ultragenyx CEO Emil Kakkis has been watching and advising the former investment banker as he navigated the deep waters of drug development.

Just as Solid is getting back up on its feet after a yearlong clinical hold, Kakkis has decided to jump in for a formal alliance.

With a $40 million upfront, Ultragenyx is grabbing 14.45% of Solid’s shares $SLDB and the rights to its microdystrophin construct for use in combination with AAV8 vectors. Solid’s lead program, which utilizes AAV9, remains unaffected. The company also retains rights to other applications of its transgene.

News brief­ing: Gilead com­pletes $21B buy­out of Im­munomedics; In­nate re­ceives $50M mile­stone pay­ment from As­traZeneca

Gilead’s $21 billion mega-acquisition of Immunomedics is now officially complete, the companies announced Friday morning.

The full merger process took a little over a month, with Gilead and Immunomedics signing an agreement on Sept. 13. Gilead acquired all outstanding stock of Immunomedics for $88 per share, a 108% premium on the previous day’s closing price.

Gilead’s big prize was Trodelvy, approved in July for the treatment of metastatic triple-negative breast cancer. The drug also impressed at last month’s ESMO conference, reducing the risk of death by 52% in a Phase III study.

A top drug pro­gram at Bay­er clears a high bar for CKD — open­ing the door to an FDA pitch

Over the past 4 years, Bayer has been steering a major trial through a pivotal program to see if their drug finerenone could slow down the pace of chronic kidney disease in patients suffering from both CKD as well as Type 2 diabetes.

Today, their team jumped on a virtual meeting hosted by the American Society of Nephrology to offer a solid set of pivotal data to demonstrate that the drug can delay dialysis or a kidney replacement as well as cardio disease, while also adding some worrying signs of hyperkalemia among the patients taking the drug. And they’re hustling it straight to regulators in search of an approval for kidney disease and cardio patients — one of the toughest challenges in the book, as demonstrated by repeated past failures.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,400+ biopharma pros reading Endpoints daily — and it's free.

Michel Vounatsos, Biogen CEO (via YouTube)

UP­DAT­ED: Bio­gen spot­lights a pair of painful pipeline set­backs as ad­u­canum­ab show­down looms at the FDA

Biogen has flagged a pair of setbacks in the pipeline, spotlighting the final failure for a one-time top MS prospect while scrapping a gene therapy for SMA after the IND was put on hold due to toxicity.

Both failures will raise the stakes even higher on aducanumab, the Alzheimer’s drug that Biogen is betting the ranch on, determined to pursue an FDA OK despite significant skepticism they can make it with mixed results and a reliance on post hoc data mining. And the failures are being reported as Biogen was forced to cut its profit forecast for 2020 as a generic rival started to erode their big franchise drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,400+ biopharma pros reading Endpoints daily — and it's free.

Stephen Hahn, FDA commissioner (AP Images)

As FDA sets the stage for the first Covid-19 vac­cine EUAs, some big play­ers are ask­ing for a tweak of the guide­lines

Setting the stage for an extraordinary one-day meeting of the Vaccines and Related Biological Products Advisory Committee this Thursday, the FDA has cleared 2 experts of financial conflicts to help beef up the committee. And regulators went on to specify the safety, efficacy and CMC input they’re looking for on EUAs, before they move on to the full BLA approval process.

All of this has already been spelled out to the developers. But the devil is in the details, and it’s clear from the first round of posted responses that some of the top players — including J&J and Pfizer — would like some adjustments and added feedback. And on Thursday, the experts can offer their own thoughts on shaping the first OKs.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,400+ biopharma pros reading Endpoints daily — and it's free.

Biond­Vax stock im­plodes af­ter a big PhI­II gam­ble for its uni­ver­sal flu vac­cine fails

After flying high on Wall Street for the last few months of a pandemic, BiondVax’s stock and dreams of getting approval for its universal flu vaccine hit the windshield.

The Jerusalem-based biotech announced on Friday that its only clinical candidate, M-001, failed both primary and secondary endpoints in a Phase III study. There was no statistically significant difference in reduction of flu illness and severity between the vaccine and placebo groups, according to the company. The vaccine did prove safe, if ineffective, BiondVax said.

Adrian Gottschalk, Foghorn CEO (Foghorn)

Foghorn hits Nas­daq in $120M de­but as the biotech IPO boom shows no sign of slow­ing

It’s been a record year for biotech IPOs, and the execs at Nasdaq would like nothing better than to see that momentum continue into the first half of next year.

Since January, 72 biotech and biopharma companies have hit Wall Street, according to Nasdaq head of healthcare listings Jordan Saxe, together raising $13.2 billion.

The latest is Flagship’s Foghorn Therapeutics, which priced its shares last night at $16 apiece, the midpoint of a $15 to $17 range. The Cambridge, MA-based biotech — which initially filed for a $100 million raise on Oct. 2 — is netting $120 million from a 7.5 million-share offering. The proceeds will go right into its gene traffic control platform, including two lead preclinical oncology candidates.